Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND   US53220K5048

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

05/17/2013 | 12:55pm US/Eastern
Recommend:
0

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

To get more information, click here: http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/. There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Recommend :
0
React to this article
Latest news on LIGAND PHARMACEUTICALS INC
5d ago LIGAND PHARMACEUTICALS : Licenses Captisol-enabled™ Lamotrigine to CURx Ph..
09/12 LIGAND PHARMACEUTICALS : Expands License with CURx Pharmaceuticals
09/09 LIGAND PHARMACEUTICALS : Licenses Captisol-enabled™ Lamotrigine to CURx Ph..
09/05 LIGAND PHARMACEUTICALS : Assigned Patent
09/04 LIGAND PHARMACEUTICALS : Lemelson Capital Comments on Large Institutional Sellin..
09/04 LIGAND PHARMACEUTICALS : Partner GlaxoSmithKline Receives U.S. FDA Approval for ..
09/02 LIGAND PHARMACEUTICALS : FDA to OK GlaxoSmithKline Promacta/Revolade
08/27 LIGAND PHARMACEUTICALS : Partner GlaxoSmithKline Receives U.S. FDA Approval for ..
08/25 LIGAND PHARMACEUTICALS : Lemelson Capital Comments on Large Institutional Sellin..
08/21 LIGAND PHARMACEUTICALS : Plans to Introduce $225 Million of Convertible Senior N..
Dynamic quotes  
ON
| OFF